Cited by 773PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 129 of the 131 references it cites were found in a registry or an index.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Polivka, Jiri, Janku, Filip·2014·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2013.12.004

Open this paper in CoChat — free account

Abstract

Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of PI3K/AKT/mTOR in the clinic and many others are in preclinical development as well as being tested in early clinical trials for many different types of cancer. This review focuses on targeted PI3K/AKT/mTOR signaling from the perspective of novel molecular targets for cancer therapy found in key pathway members and their corresponding experimental therapeutic agents. Various aberrant prognostic and predictive biomarkers are also discussed and examples are given. Novel approaches to PI3K/AKT/mTOR pathway inhibition together with a better understanding of prognostic and predictive markers have the potential to significantly improve the future care of cancer patients in the current era of personalized cancer medicine.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2013.12.004

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879

Show all 131 references

Research works printed but not linked: 1

Janku, 2011, Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors, Cancer Res, 71

Sorted by citations

Items 601–700 of 773

Activation of the Akt signalling pathway as a prognostic indicator in canine soft tissue sarcoma
Miyanishi, K., Nururrozi, A., Igase, M., Tanabe, M., Sakurai, M., Sakai, Y., Shimonohara, N., Murakami, M., & Mizuno, T. (2023) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2023.08.007 · Cited by 5
A Natural Organic Compound “Decursin” Has Both Antitumor and Renal Protective Effects: Treatment for Osteosarcoma
Hayashi, D., Shirai, T., Terauchi, R., Tsuchida, S., Mizoshiri, N., Mori, Y., Shimomura, S., Mazda, O., & Takahashi, K. A. (2023) · Journal of Oncology · doi:10.1155/2023/5445802 · Cited by 5
Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors
Rubinfeld, H., Cohen, O., Kammer, A., Yang, G., Cohen, Z. R., Hadani, M., & Shimon, I. (2015) · Neuroendocrinology · doi:10.1159/000442205 · Cited by 5
Determination of comprehensive in silico determinants as a strategy for identification of novel PI3Kα inhibitors
Srivastava, S., Vengamthodi, A., Singh, I., Choudhary, B. S., Sharma, M., & Malik, R. (2019) · Structural Chemistry · doi:10.1007/s11224-019-01303-2 · Cited by 5
Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement
Purwanto, I., Dwiprahasto, I., Aryandono, T., & Mubarika, S. (2020) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci005201202009 · Cited by 5
Applications and prospects of targeted therapy for neuroblastoma
Wang, J., Yao, W., & Li, K. (2020) · World Journal of Pediatric Surgery · doi:10.1136/wjps-2020-000164 · Cited by 5
Long noncoding RNA-miRNA-mRNA axes multiple roles in osteosarcoma
Malakoti, F., Alemi, F., Karimzadeh, H., Asemi, Z., Asadi, M., Ghobadi, H., Soleimanpour, J., & Yousefi, B. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101090 · Cited by 5
miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer
Pedroza, D. A., Ramirez, M., Rajamanickam, V., Subramani, R., Margolis, V., Mehmetoglu-Gurbuz, T., Estrada, A., & Lakshmanaswamy, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.710337 · Cited by 6
Nuclear Factor-κB Activating Protein Plays an Oncogenic Role in Neuroblastoma Tumorigenesis and Recurrence Through the Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Pathway
Liu, J., Zhang, M.-Y., Kan, Y., Wang, W., Liu, J., Gong, J.-H., & Yang, J.-G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.622793 · Cited by 5
Semisynthesis and biological evaluation of (+)-sclerotiorin derivatives as antitumor agents for the treatment of hepatocellular carcinoma
Hai, Y., Geng, J., Li, P.-J., Ma, W.-P., Wang, C.-F., Wei, M., Hou, X., Chen, G., Gu, Y., Liu, M., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114166 · Cited by 5
SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice
Kodigepalli, K. M., Li, M., Bonifati, S., Panfil, A. R., Green, P. L., Liu, S., & Wu, L. J. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1550955 · Cited by 5
New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Verma, P., Mittal, P., Singh, A. K., & Singh, I. K. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666191018172926 · Cited by 5
Cyclin B2 facilitates glycolysis and tumor progression in pancreatic ductal adenocarcinoma by promoting histone lactylation
Ma, B., Li, X., Ma, Z., Yin, Z., Gao, L., Wang, Y., Shi, J., Liu, X., & Chen, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-15172-y · Cited by 4
LAMC1 is a Novel Prognostic Factor and a Potential Therapeutic Target in Gastric Cancer
Xi, D., Jia, Q., Liu, X., Zhang, L., Xu, B., Ma, Z., Ma, Y., Yu, Y., Zhang, F., & Chen, H. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s353289 · Cited by 4
Triptonide Inhibits the Cervical Cancer Cell Growth via Downregulating the RTKs and Inactivating the Akt‐mTOR Pathway
Zhou, L.-N., Peng, S.-Q., Chen, X.-L., Zhu, X., Jin, A., Liu, Y.-Y., Zhu, L., & Zhu, Y.-Q. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8550817 · Cited by 4
Synergistic anti-proliferative and apoptotic effect of NVP-BEZ235 and curcumin on human SH-SY5Y neuroblastoma cells
Çetin, F., Kosba, S., Abdik, H., & Bolat, Z. B. (2023) · Medical Oncology · doi:10.1007/s12032-023-02239-8 · Cited by 4
The state of targeted therapeutic pharmacological approaches in pediatric neurosurgery: report from the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference 2024
Frassanito, P., Thomale, U. W., Obersnel, M., Romano, A., Leblond, P., Knerlich‐Lukoschus, F., Due‐Tønnessen, B. J., Thompson, D. N. P., Rocco, F. D., & the CPN Lyon 2024 Consensus Conference Group (2025) · Child s Nervous System · doi:10.1007/s00381-025-06799-0 · Cited by 6
Silencing of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human lung cancer cells
Hu, X., Guo, W., CHEN, S., Xu, Y., Li, P., Wang, H., Chu, H., LI, J., Du, Y., Chen, X., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4451 · Cited by 4
Involvement of upregulation of fibronectin in the pro‑adhesive and pro‑survival effects of glucocorticoid on melanoma cells
Huang, G., Qi, M., Li, X., Tang, F., & Zhu, L. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8269 · Cited by 4
Kaposi's sarcoma-associated herpes virus-derived microRNA K12–1 over-activates the PI3K/Akt pathway to facilitate cancer progression in HIV-related gastrointestinal Kaposi's sarcoma
Huang, X., Rao, W., Wang, C., Lu, J., Li, Z., Kong, W., Feng, Y., Xu, T., Apaer, R., & Gao, F. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.04.001 · Cited by 4
Mechanisms of Chemoresistance in High-Grade Gliomas
SohrabiAsl, M., Iranmehr, A., & Hanaei, S. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_185 · Cited by 4
Immunohistochemical evaluation of the mTOR pathway in intra‐oral minor salivary gland neoplasms
Diamanti, S., Nikitakis, N. G., Rassidakis, G. Z., Doulis, I., & Sklavounou, A. (2016) · Oral Diseases · doi:10.1111/odi.12504 · Cited by 4
Antiprostate Cancer Activity of Ineupatolide Isolated from Carpesium cernuum L.
Huang, Y., Mao, J., Zhang, L., Guo, H.-W., Chen, Y., & Chen, M. (2021) · BioMed Research International · doi:10.1155/2021/5515961 · Cited by 4
Ipriflavone Suppresses Growth of Esophageal Squamous Cell Carcinoma Through Inhibiting mTOR In Vitro and In Vivo
Shi, X., Zhang, Y., Xie, X., Pang, M., Laster, K. V., Li, J., Ma, X., Liu, K., Dong, Z., & Kim, D. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648809 · Cited by 4
Myricetin can control metastasis and invasion by suppressing ATF2-related signaling pathway in Rapamycin-resistant HepG2 hepatocellular cancer cells
Erdoğan, Ö., & Çevik, Ö. D. (2023) · Journal of Research in Pharmacy · doi:10.29228/jrp.337 · Cited by 3
Pyroptosis‐related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma
Zhang, Y., Wang, Y., Weng, J., Chen, J., Zheng, Y., Xia, Y., Huang, Z. L., Zhao, L., Chen, X., Tang, H., et al. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23805 · Cited by 3
Ethyl gallate suppresses ferroptosis and alleviates intervertebral disc degeneration through targeting AKT1
Qiu, J., Liu, X., Li, H., Zhou, X., Zhang, Y., Chen, Z., Li, K., Wu, Y., Zhang, X., Zhou, Y., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117335 · Cited by 3
Wenyang Decoction Ameliorates DSS‐Induced Ulcerative Colitis by Regulating Macrophage Polarization and the PI3K/AKT/mTOR/HIF‐1α Signaling Pathway
Li, S., 袁光辉, Chen, C., Lu, J., & Zhang, X. (2026) · Mediators of Inflammation · doi:10.1155/mi/7737168 · Cited by 3
The mechanism of the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma: current developments and future prospects
Zou, C., Wang, Y. J., Chen, Q., Shi, J., Wu, X., & Luo, Q. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1745024 · Cited by 3
Cytochrome c as a central regulator of mitochondrial function in cancer metabolism
Shabir, A., Sofi, S., Jan, N., Haq, B. U., Qayoom, H., & Mir, M. A. (2026) · Discover Oncology · doi:10.1007/s12672-026-05014-z · Cited by 3
Silencing of CPSF7 inhibits the proliferation, migration, and invasion of lung adenocarcinoma cells by blocking the AKT/mTOR signaling pathway
An, W., & Yu, F. (2022) · Open Medicine · doi:10.1515/med-2022-0570 · Cited by 3
A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib
Bayram, E., Khatib, G., Güney, İ. B., Bağır, E. K., Gulec, H. R., Boğa, İ., & Paydaş, S. (2023) · Genes · doi:10.3390/genes14081632 · Cited by 3
Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma
Biczó, Á., Sahgal, A., Verlaan, J., PATEL, S. R., Szövérfi, Z., Schultheiß, M., Rhines, L. D., Reynolds, J., Laufer, I., Gasbarrini, A., et al. (2025) · Global Spine Journal · doi:10.1177/21925682241227917 · Cited by 3
Identifying the function of kinesin superfamily proteins in gastric cancer: Implications for signal transduction, clinical significance, and potential therapeutic approaches
Sanghvi, G. V., Roopashree, R., Kashyap, A., Sabarivani, A., Ray, S., & Bhakuni, P. N. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102571 · Cited by 3
Target prioritization of novel substituted 5-aryl-2-oxo-/thioxo-2,3-dihydro-1H-benzo[6,7]chromeno[2,3-d]pyrimidine-4,6,11(5H)-triones as anticancer agents using in-silico approach
Bhayye, S. S., Brahmachari, G., Nayek, N., Roy, S., & Roy, K. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1606735 · Cited by 3
Research progress on the interaction between long non‑coding RNAs and RNA‑binding proteins to influence the reprogramming of tumor glucose metabolism (Review)
Wu, W., & Wen, K. (2022) · Oncology Reports · doi:10.3892/or.2022.8365 · Cited by 3
Comprehensive Mutation Profiling of Colorectal Cancer Patients With Lung or Liver Metastasis by Targeted Next-Generation Sequencing
Hu, C.-T., Wang, J., Hou, T., Yan, Z.-W., Zu, L., Fu, G., & Shen, W. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231185285 · Cited by 3
Development of small-molecule inhibitors that target PI3Kβ
Yu, Y., Gu, D., Cai, L., Yang, H., & Sheng, R. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103854 · Cited by 3
Virtual docking screening and quantitative structure-activity relationship studies to explore AKT and PI3K inhibitors acting on mTOR in cancers by theoretical biology and medical modeling
Kandoussi, I., Abbou, H., Haddoumi, G. E., Mansouri, M., Belyamani, L., & Ibrahimi, A. (2023) · Współczesna Onkologia · doi:10.5114/wo.2023.133709 · Cited by 3
Ultrasonic-assisted hydrothermal fabrication of selenium nanorods and their anticancer properties in prostate cancer cells and associated signaling pathway
Du, S., & Kang, S. (2024) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2024.105714 · Cited by 3
CD200R promotes high glucose-induced oxidative stress and damage in human retinal pigment epithelial cells by activating the mTOR signaling pathway
Hu, Y., Wei, T., Gao, S., Gao, N., Chen, L., & Cheng, Q. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102381 · Cited by 3
ASPSCR1::TFE3-mediated upregulation of insulin receptor substrate 2 (IRS-2) activates PI3K/AKT signaling and promotes malignant phenotype
Ishiguro, N., & Nakagawa, M. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106676 · Cited by 3
Novel insights into sheep domestication in Southwest Asia based on genome‐wide sequencing
Fang, W., Liu, Y., Zhang, H., Cai, Y., Cheng, H., Xiao, C., Jiang, Y., Jin, H., Li, R., & Cao, Y. (2025) · Animal Genetics · doi:10.1111/age.13500 · Cited by 3
Recent Advances on Nucleotide Analogs and Mimetics
Xavier, N. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12655-1 · Cited by 3
RETRACTED ARTICLE: Neferine hinders choriocarcinoma cell proliferation, migration and invasion through repression of long noncoding RNA-CHRF
Wang, G., Wang, P., Yan, X., & Liu, J. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1671429 · Cited by 3
Retracted
[Effect of danusertib on cell cycle, apoptosis and autophagy of hepatocellular carcinoma HepG2 cells in vitro].
Zhu, Q., Luo, M., Zhou, C., Chen, Z., Huang, W., Huang, J., Zhao, S., & Yu, X. (2018) · Europe PMC (PubMed Central) · doi:10.12122/j.issn.1673-4254.2018.12.13 · Cited by 3
Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers
Kandoussi, I., Benherrif, O., Lakhlili, W., Taoufik, J., & Ibrahimi, A. (2020) · Współczesna Onkologia · doi:10.5114/wo.2020.93334 · Cited by 3
Systems Pharmacology-Based Identification of Mechanisms of Action of Bolbostemma paniculatum for the Treatment of Hepatocellular Carcinoma
Wang, L., Liao, C., Li, X., Dai, R., Ren, Q.-W., Shi, H., Wang, X., Feng, X., & Xu, C. (2021) · Medical Science Monitor · doi:10.12659/msm.927624 · Cited by 3
QSAR modeling and structure based virtual screening of new PI3K/mTOR inhibitors as potential anticancer agents
Oluić, J., Nikolic, K. M., Vučićević, J., Gagić, Ž., Filipić, S., & Agbaba, D. D. (2017) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-981-10-4166-2_58 · Cited by 3
A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death
Xie, Y., Li, C., Huang, Y., Jia, Z., & Cao, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20257 · Cited by 3
Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer
Lü, C., Qie, Y., Liu, S., Wu, C., Zhang, Z., Liu, R., Yang, K., Hu, H., & Xu, Y. (2018) · DNA and Cell Biology · doi:10.1089/dna.2018.4193 · Cited by 3
Essential Role of mTOR Signaling in Human Retinal Pigment Epithelial Cell Regeneration After Laser Photocoagulation
Madrakhimov, S. B., Yang, J. Y., Park, H. Y., & Park, T. K. (2018) · Lasers in Medical Science · doi:10.1007/s10103-018-2692-5 · Cited by 3
MAPK and AKT Pathway Intersection in Neuroblastoma Cells
Yildiz, A. (2017) · Current Trends in Biomedical Engineering & Biosciences · doi:10.19080/ctbeb.2017.02.555580 · Cited by 3
The Piezo1 Mechanosensitive Ion Channel Promotes Melanoma Malignant Progression by Activating PI3K-AKT SignalingPreprint
zhang, S., Cao, S., Gong, M., Zhang, W., zhang, W., Zhu, Z., Wu, S., Shi, Y. X., Wang, L., Yue, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-638409/v1 · Cited by 3
Cellular and Molecular Mechanisms of Tumor Promotion
Bode, A. M., & Zhang, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00059-0 · Cited by 3
N(6)-methyladenosine modification of ADGRA3 by ZC3H13 suppresses papillary thyroid cancer cell malignancy by inactivating the PI3K/Akt/mTOR signaling pathway
Li, C., Zhang, L., & Yan, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-03482-3 · Cited by 2
The Role of PI3K Inhibition in Suppressing Pancreatic Cancer Progression: Mechanistic Insights From Copanlisib Studies
Li, Y., Wu, J., Wan, S.-J., & Zhu, J. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70144 · Cited by 2
A Comprehensive Analysis of Natural Bioactive Molecules for the Treatment and Control of Glioblastoma Multiforme (GBM) Targeting Underlying Molecular Mechanism
Parvez, A., Rahman, M. A., Shimki, A. I., Biswas, P., Hasan, M. H., Imtiaz, M., Sultana, A., Islam, S., Faraque, A., Amin, M. F., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501413 · Cited by 4
Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2–TP53, EGFR, and PI3K/AKT/mTOR
Singh, N. K., Ahmad, F., & Husain, A. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156506 · Cited by 2
A Comprehensive Look at Oromaxillofacial and Laryngopharyngeal Cancers
Shabestari, S. B., Shirinbak, I., & Azadarmaki, R. (2017) · Springer eBooks · doi:10.1007/978-3-319-64550-6_11 · Cited by 2
ABCA4 mediated traumatic proliferative vitreoretinopathy associated with PI3K/Akt signaling pathway
Menghua, W., & Hu, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27024 · Cited by 2
The Anti-proliferative Effect of Caffeic Acid and Dactolisib on Human Cervical Carcinoma HeLa Cell Line
Bolat, Z. B. (2024) · Cumhuriyet Science Journal · doi:10.17776/csj.1394831 · Cited by 2
MLIP and Its Potential Influence on Key Oncogenic Pathways
Hamwi, M. N., Elsayed, E., Dabash, H., Abuawad, A., Aweer, N. A., Zeir, F. A., Pedersen, S., Al-Mansoori, L., & Burgon, P. G. (2024) · Cells · doi:10.3390/cells13131109 · Cited by 2
Longitudinal Study of Transcriptomic Changes Occurring over Six Weeks of CHOP Treatment in Canine Lymphoma Identifies Prognostic Subtypes
Mee, M. W., Faulkner, S., Wood, G. A., Woods, J. P., Bienzle, D., & Coomber, B. L. (2024) · Veterinary Sciences · doi:10.3390/vetsci11110540 · Cited by 2
Unravelling the oncogenic potential and prognostic significance of MAPT in breast cancer: An In-Silico inhibition of MAPT by paclitaxel
Jan, A., Sofi, S., & Mir, M. A. (2025) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2025.100134 · Cited by 3
Constructing a prognostic model based on MPT-related genes and investigate the characteristics of immune infiltration in bladder cancer
Yang, L., Zhang, Z., Xu, M., Shang, M., Wang, H., & Liu, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-02222-x · Cited by 2
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
Jankú, F., Jegede, O. A., Puhalla, S. L., Konstantinopoulos, P. A., Meric‐Bernstam, F., Zwiebel, J. A., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00265 · Cited by 2
Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance
Castven, D., Czauderna, C., & Marquardt, J. U. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-56197-4_4 · Cited by 2
The Incidence of mTOR Marker in Tracheal Adenoid Cystic Carcinoma by Immunohistochemical Staining
Toutkaboni, M. P., Farahani, M., Sadegh, A., Kiani, A., Sadr, M., Taghavi, K., & Abedini, A. (2020) · Advances in respiratory medicine · doi:10.5603/arm.a2020.0120 · Cited by 2
[Clinical Value of Cerebrospinal Fluid ctDNA in Patients with Non-small Cell Lung Cancer Meningeal Metastasis].
Zhang, K., Dai, Z., Liu, S., Li, D., Yang, D., & Cui, S. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.42 · Cited by 2
Rigosertib is more potent than wortmannin and rapamycin against adult T‐ cell leukemia‐lymphoma
Neghab, M. G., Jalili‐Nik, M., Soltani, A., Afshari, A. R., Hassanian, S. M., Rafatpanah, H., Rezaee, S. A., Sadeghnia, H. R., Azimi, S. A., & Mashkani, B. (2023) · BioFactors · doi:10.1002/biof.1985 · Cited by 3
Metabolomics and Cancer: Identification of Biomarkers from Plant-Based Pharmaceuticals Using an Integrated Approach
Manickavasagam, G., Mahendran, T. R., & Lim, V. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_223 · Cited by 2
Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding protein 3 expression
Yamamoto, Y., Fujita, K., Munari, E., Uemura, M., Miyamoto, H., & Netto, G. J. (2019) · International Journal of Urology · doi:10.1111/iju.13940 · Cited by 2
THE EFFECTS OF METFORMIN ON PANCREATIC CANCER METABOLISM
Cantoria, M. J. (2014) · UA Campus Repository (The University of Arizona) · Cited by 2
Dihydroartemisinin Promotes Neural Stem Cell Differentiation into Oligodendrocytes via STAT6/Chi3l3 Signaling Pathway in Microglia
Li, M., Ran, Q., Du, X., Chen, K., Yang, Q., Zhu, X., & Li, Q. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3591 · Cited by 1
Quercetin Promotes Abdominal Aortic Aneurysm Regression Through the RAGE/PI3K/AKT/mTOR Axis
Yang, X., Wang, Y., Xin, G., Li, J., Xu, L., Zhang, G., & Yang, H. (2024) · Natural Product Communications · doi:10.1177/1934578x241286438 · Cited by 1
Precision Oncology: A Method to Maximize Quality of Life
Maheen, A., Zaidi, S., Badar, M. R., Haque, M. A., Khan, Y. T., Jilani, L. Z., Mohsin, S. S., Akhtar, K., & Badar, M. S. (2025) · Interdisciplinary cancer research · doi:10.1007/16833_2024_489 · Cited by 1
Astrocyte activation: A key mediator underlying chronic intermittent hypoxia-induced cognitive dysfunction
Chu, H., Jiang, W., Zuo, N., Sun, F., Wu, C., & Liu, S. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106692 · Cited by 1
Synergistic Efficacy of Chidamide and LB100 in Sézary Syndrome via TNC Downregulation and PI3K / AKT / mTOR Dephosphorylation
Chen, N., Wang, Y., Luo, L., Hua, X., Xue, Q., Gong, B., Zhang, Y., & Shi, W. (2025) · Cancer Science · doi:10.1111/cas.70184 · Cited by 1
Modulating the BI ‐1( TMBIM6 )/ AKT Signaling Pathway by Licochalcone D Treatment Inhibits Human Melanoma Cell Growth
Hwang, S., Lee, C., Wi, K., Kim, Y. W., Nam, S., Lee, J. Y., Yoon, G., Bang, G., Shim, J., & Lee, M. (2025) · Phytotherapy Research · doi:10.1002/ptr.70089 · Cited by 1
Novel magnolol–sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization
Peng, Y., Liu, B., Guo, Y., Chen, J., Chen, H., Liu, X., Huang, J., Luo, D., Hong, Y., Wu, D., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00733j · Cited by 1
Branched-chain amino acid transaminases as promising targets in tumor therapy
Zhang, W., Shen, J., Ding, X., Liu, H., Wang, X., & Feng, D. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1712076 · Cited by 2
Detecting the spike protein of COVID-19 deteriorates insulin resistance of skeletal muscle in Chinese diabetes patients: analysis of blood glucose metabolism
Zhang, T., Peng, H., Chen, C., Zheng, H., Yang, D., & Liu, Y. (2026) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2025.2610476 · Cited by 1
WITHDRAWN: SIKE1 deficiency accelerates hepatic ischemia/reperfusion (IR) injury through enhancing Toll-like receptor-3-regulated inflammation
Yang, X., Jiang, H., & Shi, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.125 · Cited by 1
Retracted
The AKT antagonist AZD5363 suppresses features associated with cancer progression in human larynx cancer cells
Şanli, F., Barlak, N., KILINÇ, A., Çapik, Ö., Aytatlı, A., & Karataş, Ö. F. (2020) · The European Research Journal · doi:10.18621/eurj.624088 · Cited by 1
Molecular Processes Involved in Pancreatic Cancer and Therapeutics
Makar, S., Ghosh, A., divya, D. D., Shivhare, S., Kumar, A., & Singh, S. K. (2020) · Current Chemical Biology · doi:10.2174/2212796814999201008130819 · Cited by 1
The Role of Mammalian Target of Rapamycine Signaling Pathway in Central Nervous System Cancers: A Review
Serej, F. A., Serej, H. A., Kalan, A. E., Mehdipour, A., Serej, Z. A., Bravan, B., & Shiri‐Shahsavar, M. R. (2020) · The Journal of Qazvin University of Medical Sciences · doi:10.32598/jqums.24.5.10 · Cited by 1
43-O-(β- D -glucoside)-rapamycin, a microbial conversion product by Bacillus subtilis CGMCC7764
Chen, X.-M., Yang, G., Chen, X.-Q., Jin, D.-W., Yu, H., Cheng, Y., & Huang, J. (2022) · Biocatalysis and Biotransformation · doi:10.1080/10242422.2022.2108707 · Cited by 1
New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme
Singh, M., Jindal, D., Agarwal, V., Pathak, D., Sharma, M., Pancham, P., Mani, S., & Rachana, R. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00118 · Cited by 1
The Expression of ARMCX1 in Gastric Cancer Contributes to Prognosis and Influences Chemotherapy
Lv, C., Yang, D., Zhang, D., Shen, J., Wang, Z., He, S., Meng, L., Song, J., & Zhao, J. (2023) · Journal of Immunology Research · doi:10.1155/2023/2623317 · Cited by 1
Phosphoinositide and redox dysregulation by the anticancer methylthioadenosine phosphorylase transition state inhibitor
Salita, T., Rustam, Y. H., Hofferek, V., Jackson, M., Tollestrup, I., Sheridan, J. P., Schramm, V. L., Evans, G. B., Reid, G. E., & Munkacsi, A. B. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159346 · Cited by 1
Link between miR-19b and the mTOR signaling pathway in cancer prognosis*
Feng, Y., Maman, S. T. D., Li, S., He, D., & Tu, J. (2020) · Oncology and Translational Medicine · doi:10.1007/s10330-020-0422-2 · Cited by 1
Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery
Martell, K., McIntyre, J. B., Abedin, T., Kornaga, E. N., Chan, A. M. Y., Enwere, E. K., Köbel, M., Dean, M. L., Phan, T., Ghatage, P., et al. (2023) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000978 · Cited by 1
Macrolides for Cancer
Shinoda, M. (2024) · Progress in inflammation research · doi:10.1007/978-3-031-42859-3_12 · Cited by 1
Mitochondrial Energy Metabolism in Carcinogenesis
Kurhaluk, N., & Tkaczenko, H. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_226 · Cited by 1
Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV
Xiao, X., Fu, H., Qin, H., Xu, L., Gu, J., Zhang, Z., Ya, H., Jiang, K., Jian, Z., & Li, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1422801 · Cited by 1
Potential Drug Strategies to Target Coronaviruses
Sarkar, K., & Sil, P. C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-85109-5_7 · Cited by 1
Potential Mechanism Of Nanoparticles Targeting Cancer Metabolic Pathways: Novel Approaches For Cancer Treatment
Din, Z. U., Khan, Y., Zia, A., Anbreen, N., & Sultan, R. (2023) · Advances In Clinical And Medical Research · doi:10.52793/acmr.2023.4(3)-61
Molecular Targets in Gynecologic Cancers
Growdon, W., Foster, R., & Rueda, B. R. (2014) · doi:10.1002/9781118655344.ch1 · Cited by 1
Systematic Understanding of the Mechanism of Pristimerin via Computational Target FishingPreprint
Li, Z., Hu, C., Zhen, Y., Pang, B., Yi, H., & Chen, X. (2018) · Preprints.org · doi:10.20944/preprints201809.0564.v1

Authors: Polivka, J., & Janku, F.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2014-05
Volume: 142
Issue: 2
Pages: 164-175
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2013.12.004
OpenAlex: W2132052921
Cited by: 765
References: 131
Citations by year: 2026: 20 · 2025: 31 · 2024: 41 · 2023: 71 · 2022: 56 · 2021: 90 · 2020: 80 · 2019: 103 · 2018: 63 · 2017: 71 · 2016: 51 · 2015: 59 · 2014: 28
FWCI: 4.39
Type: journal article
Language: en
Open access: closed
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: PI3K/AKT/mTOR pathway, targeted cancer therapy, molecular targets, PI3K inhibitors, mTOR inhibitors, everolimus, temsirolimus, MAPK signaling, oncogenic mutations, tumor suppressor, prognostic factors, predictive biomarkers, precision oncology, carcinogenesis
MeSH terms: Phosphoinositide-3 Kinase Inhibitors, Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Design, Signal Transduction, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks